Rep. Gilbert Ray Cisneros Jr. (D-CA) Sells Insulet (PODD) Stock

Rep. Gilbert Ray Cisneros Jr., a Democrat from California's 31st district, sold shares of Insulet Corporation (PODD) on September 18, 2026. The transaction was valued between $1,001 and $15,000 and was reported on October 12, 2026.

Other Institutional Activity in Insulet Corporation

Several institutional investors have been active with Insulet shares recently. Blackrock Inc. grew its holdings by 314,330 shares, bringing its total to about 6.69 million shares worth approximately $943.99 million. State Street Corporation added 155,162 shares, ending with around 3.20 million shares valued at about $451.18 million. In contrast, Vanguard Capital Management LLC trimmed its position by 54,037 shares, leaving it with 4.53 million shares worth about $638.52 million.

Insulet Corporation Stock Up 1.7%

Insulet's stock is currently trading around $142.22 as of October 16, 2026. This price is above its 52-week low of $126.40 but significantly below its 52-week high of $354.88. The stock is also trading below its 50-day moving average of $140.39, indicating a recent downward trend.

Recent Earnings

For the trailing twelve months, Insulet reported revenue of approximately $3.05 billion, with a year-over-year growth of 23.5%. The company has an earnings per share (EPS) of $5.34 and a return on equity (ROE) of 26.0%. Insulet's next earnings report is scheduled for November 4, 2026.

Insider Buying and Selling at Insulet Corporation

Insider trading activity has been noted at Insulet. On February 25, 2026, Director Michael R Minogue bought 2,030 shares at an average price of $246.23, totaling around $499,847. Other directors, including Luciana Borio, Timothy C Stonesifer, and Elizabeth H Weatherman, made sales on June 3, 2026. Borio sold 418 shares at $143.27, while Stonesifer and Weatherman sold 2,790 and 3,450 shares at $143.51 and $144.20, respectively, totaling about $400,393 and $497,490.

Analysts Set New Price Targets

On August 6, 2026, several analysts updated their ratings on Insulet. Canaccord Genuity maintained a 'Buy' rating with a target price of $179.00, while Leerink Partners downgraded the stock to 'Market Perform' with a target of $145.00. RBC Capital kept its 'Outperform' rating with a target of $160.00. The consensus among analysts is a 'buy' rating with a mean price target of $167.17, reflecting confidence in the company's future performance.

About Insulet Corporation

Insulet Corporation, based in Acton, Massachusetts, specializes in developing and selling insulin delivery systems for individuals with insulin-dependent diabetes. The company has been making strides in the healthcare sector, particularly with its innovative products aimed at improving patient quality of life.

Bottom Line

Rep. Gilbert Ray Cisneros Jr.'s recent sale of Insulet shares adds to his history of trading in the market, including previous sales of Workday and W. R. Berkley. Investors should keep an eye on Insulet's upcoming earnings report on November 4, 2026, for further insights into its financial health.